FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

68 letters match. Newest first.

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  4. Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.

    Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.

    High risk
  5. IF Co-Pack, LLC dba Initiative Foods

    FDA warns Initiative Foods, a Sanger, California baby food maker, that it failed to control patulin, a mold toxin, in fruit pouches.

    High risk
  6. Rama Food Manufacture Corp.

    FDA warns Rama Food Manufacture after inspections found insanitary conditions and preventive-control failures at its California ready-to-eat rice noodle plants.

    High risk
  7. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  8. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  9. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  10. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  11. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  12. Tipical Latin Food, Corp. DBA La Pradera

    FDA warned La Pradera of Doral, Florida, that its ready-to-eat Venezuelan-style cheeses are adulterated; an inspection found no food safety plan and pests.

    High risk
  13. Neogen Corporation

    FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.

    High risk
  14. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  15. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  16. Middlefield Original Cheese Cooperative

    FDA warns Middlefield Original Cheese Cooperative about Listeria and insanitary conditions in its ready-to-eat cheese.

    High risk
  17. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  18. Union Trade Inc.

    FDA warns Union Trade Inc. that it lacked required foreign supplier verification for imported radish, peanuts, mushrooms, and fruit.

    High risk
  19. Raaw Energy LLC

    FDA: Raaw Energy's frozen raw dog food contained Salmonella, Listeria and Campylobacter and was made under insanitary conditions.

    High risk
  20. Viva Raw LLC

    Viva Raw LLC's raw pet foods were found contaminated with Salmonella and Listeria, leading to a Class I recall.

    High risk
  21. Fresenius Medical Care AG & Co. KGaA

    Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.

    High risk
  22. Reliance Life Sciences Private Limited

    FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.

    High risk
  23. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  24. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  25. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  26. Safrel Pharmaceuticals LLC

    FDA warned Safrel Pharmaceuticals, an OTC drug labeler in Dayton, New Jersey, that it lacked quality oversight of its suppliers and shipped adulterated drugs.

    High risk
  27. Nipro Renal Solutions USA, Corporation

    Nipro Renal Solutions USA released hemodialysis dialysate lots with out-of-spec endotoxin (bacterial toxin) and had widespread quality-system failures, FDA says.

    High risk
  28. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  29. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  30. Koven Technologies, Inc.

    FDA warns Koven Technologies that its Bidop 3 Doppler was labeled for fetal use without clearance and had quality system violations.

    High risk
  31. Shimoga Chemicals

    FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

    High risk
  32. Shang Hao Jia, Inc.

    Shang Hao Jia lacked required foreign supplier verification for imported tofu, crackers and almond cake, including a recalled tofu with undeclared sesame.

    High risk
  33. International Medication Systems Limited

    FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.

    High risk
  34. Huons Co., Ltd.

    FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

    High risk
  35. ZOLL Medical Corporation

    FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.

    High risk
  36. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  37. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  38. Shantou Qiwei Industry Co., LTD

    FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

    High risk
  39. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk
  40. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  41. Aversa's Italian Bakery

    FDA warns Aversa's Italian Bakery over missing food safety plan and undeclared sesame/milk allergens in ready-to-eat rolls.

    High risk
  42. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  43. Best Buy Bones, Inc.

    Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.

    High risk
  44. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  45. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  46. Ridley USA Inc.

    Ridley USA's Iowa City medicated feed plant put monensin into cattle feed instead of the intended drug, killing at least 16 cattle.

    High risk
  47. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  48. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  49. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  50. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk